In solution-phase manufacturing of C-terminal tyrosyl peptide active pharmaceutical intermediates, L-tyrosine methyl ester hydrochloride is charged as a carboxyl-protected nucleophile after in situ neutralization with a tertiary amine. The hydrochloride salt is slurried in anhydrous N,N-dimethylformamide and treated with N-methylmorpholine until the free base concentration reaches 1.0–1.05 molar equivalents relative to the N-acylated amino acid acyl donor; the liberated HCl is converted to N-methylmorpholinium chloride and remains in solution without competing for the carbodiimide. The acyl donor is activated with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1-hydroxybenzotriazole hydrate in the same vessel at 0–5°C, while the pH is maintained between 8.0 and 8.5 through an automated dosing pump. On a 500 L glass-lined jacketed reactor with bottom drain valve and nitrogen purge, batch-to-batch variation is observed when the chloride content of the incoming hydrochloride salt exceeds the theoretical value of 15.31% w/w; excess chloride consumes the amine base and shifts the neutralization endpoint, lowering free amine concentration and producing a measurable rise in N-acyl urea byproduct. Process analytical technology is configured with a mid-infrared probe at the reactor sidearm; the disappearance of the activated ester carbonyl signal and the appearance of the amide carbonyl near 1650 cm⁻¹ are integrated into the batch record. The decanter workup uses a two-stage countercurrent extraction with ethyl acetate at 10–15°C to minimize methyl ester saponification during aqueous contact; residual water in the organic layer is removed by azeotropic distillation at 60 mbar. The coupling is monitored by HPLC with a C18 column and an aqueous acetonitrile gradient, with detection at 220 nm and a run time of 30 min. Residual solvent control follows ICH Q3C R8; the working limits are 3,000 ppm for methanol, 720 ppm for tetrahydrofuran, and 880 ppm for N,N-dimethylformamide. Water content is measured by Karl Fischer titration under USP 921 and must remain below 0.5% w/w before release. The terminal products of this process are protected tyrosyl dipeptide and tripeptide intermediates and final peptide APIs with C-terminal tyrosine residues; for materials destined to active pharmaceutical ingredient manufacturing, the starting material specification is maintained under ICH Q7 Section 7.31, and laboratory controls follow FDA 21 CFR 211.160(b).

How Are N-Protected Tyrosine Methyl Ester Derivatives Processed Under ICH Q7?

When H-Tyr-OMe·HCl is converted into N-Boc or N-Fmoc derivatives for solution-phase peptide synthesis, the reaction is run as a two-phase bicarbonate neutralization rather than as a single-solvent protection. In a 300 L glass-lined reactor charged with tetrahydrofuran and purified water at a 1:1 v/v ratio, sodium bicarbonate at 2.0–2.5 molar equivalents is used to neutralize the hydrochloride and to maintain the aqueous phase at pH 8.0–9.0. Boc anhydride is added at 1.05–1.20 molar equivalents relative to the amino ester hydrochloride, with the jacket temperature held at 5–10°C during the first 2 h to manage the exotherm from carbamate formation. The batch is then warmed to 20–25°C and held for 6–10 h with stirring at 120–150 rpm; agitation is provided by a retreat-curve impeller with a 0.45 m diameter, and impeller tip speed is kept below 1.5 m/s to avoid emulsion persistence during phase split. The methyl ester is prone to alkaline hydrolysis above pH 10.5; sodium bicarbonate systems are therefore preferred over sodium hydroxide for this intermediate class. After reaction, the phases are separated and the aqueous layer is extracted twice with ethyl acetate, followed by washing with 5% w/v sodium chloride solution. Crystallization from ethyl acetate/n-heptane in a 1:3 v/v ratio yields the protected methyl ester as a white crystalline solid; vacuum drying at 40°C for 8 h reduces water content to ≤0.5% w/w under USP 921. Process controls follow ISO 9001:2015 Clause 8.5.1, and where the protected derivative is shipped to pharmaceutical peptide manufacturers, the release protocol is aligned with ICH Q7 Section 7.1. The terminal finished products are N-Boc-L-tyrosine methyl ester and N-Fmoc-L-tyrosine methyl ester, which are subsequently used in fragment coupling or hydrolyzed to the free acid for solid-phase assembly.

Cosmeceutical Peptide Assembly with Methyl Ester Hydrochloride Salts

Because the hydrochloride salt consumes coupling reagents directly, H-Tyr-OMe·HCl is first converted to Fmoc-L-tyrosine methyl ester and then saponified to Fmoc-L-tyrosine-OH before use in Fmoc/tBu solid-phase peptide synthesis for cosmetics. The saponification uses lithium hydroxide at 1.2–1.5 molar equivalents in tetrahydrofuran/water at 0–5°C for 6–8 h; the pH is never allowed to exceed 10.5 because methyl ester hydrolysis accelerates rapidly above this value and can cleave the N-Fmoc group. In the subsequent solid-phase assembly, the resin is an aminomethylated polystyrene resin with substitution from 0.4 to 0.8 mmol/g. The tyrosyl monomer is coupled at 3.0–4.0 molar equivalents relative to resin substitution, with HATU and diisopropylethylamine at a 1:1.2 molar ratio; coupling is run at 25–30°C for 45–60 min on an automated peptide synthesizer with a 100 mmol reactor vessel. Fmoc removal uses 20% piperidine/DMF in two cycles of 10 min each; the vessel is washed with N,N-dimethylformamide after each deprotection. Moisture in the Fmoc monomer must remain below 0.3% w/w before charging to the synthesizer; higher moisture is associated with incomplete coupling and deletion sequences that are detected by UPLC at 220 nm as pre-peak shoulders. Cleavage from the resin employs a TFA:TIS:H2O 95:2.5:2.5 v/v/v cocktail for 2 h at ambient temperature, followed by precipitation in cold methyl tert-butyl ether and preparative HPLC purification. The final peptide concentrate is adjusted to 100–1,000 ppm active peptide before introduction into cosmetic finished formulations; the downstream formulator typically achieves 1–10 ppm peptide concentration in the final serum or cream. Compliance is maintained under ISO 22716:2007 Clauses 12.1 and 14.1, with safety assessment under Regulation (EC) No 1223/2009 Article 10; release purity is determined by HPLC under USP 621. Failure to neutralize residual HCl before Fmoc protection causes variable coupling efficiency and batch-to-batch peptide yield shifts exceeding 15% on production-scale runs.

For enzyme quality-control reagent lyophilization, L-tyrosine methyl ester hydrochloride is formulated as a spectrophotometrically detectable chymotrypsin substrate rather than as a building block. The substrate is dissolved at 0.2–0.5 mM in 50 mM potassium phosphate buffer adjusted to pH 7.0 with phosphoric acid; the hydrochloride contributes chloride to the solution, and the osmolality rise of 12–18 mOsm/kg observed in production-scale lots is corrected before lyophilization. The working enzyme concentration in the reconstituted reagent is 0.1–0.5 U/mL, where one unit is defined as the amount of chymotrypsin hydrolyzing 1 µmol of substrate per minute under the stated conditions. The solution is sterile-filtered through a 0.22 µm polyethersulfone membrane and filled into 2 mL borosilicate vials with 10% headspace. Lyophilization uses shelf cooling to −20°C, primary drying at 0.1 mbar for 24 h, and secondary drying at 20°C for 6 h; the condenser is held at −60°C, and vial thermocouple data show a 4–6°C product temperature offset during primary drying that is built into the cycle design. Vehicle pH above 8.5 is avoided because the methyl ester bond undergoes spontaneous base hydrolysis, which creates free tyrosine and inflates blank activity readings. Release testing includes reconstitution with water and monitoring the absorbance increase at 280 nm over 180 s using a calibrated spectrophotometer per Ph. Eur. 2.2.25; method validation is documented under ISO 17025:2017 Clause 7.2. The terminal finished product is a lyophilized chymotrypsin activity assay reagent supplied to pharmaceutical quality-control laboratories and enzyme contract testing facilities.

When N-Carboxyanhydride Polymerization Starts from Tyrosyl Methyl Ester Hydrochloride

Ring-opening polymerization of α-amino acid N-carboxyanhydrides derived from L-tyrosine methyl ester hydrochloride is run under strictly anhydrous conditions because the NCA intermediate is hydrolytically unstable. The monomer salt is converted to L-tyrosine N-carboxyanhydride using triphosgene at 0.33–0.40 molar equivalents relative to the hydrochloride salt in anhydrous tetrahydrofuran at 45–55°C for 8–12 h, with a nitrogen purge and 0.3 MPa backpressure to retain solvent. Proton scavenging is accomplished with α-pinene at 1.5–2.0 molar equivalents; FTIR monitoring of NCA formation uses the anhydride carbonyl doublet between 1810 and 1850 cm⁻¹, and the endpoint is defined as the disappearance of the amino ester hydrochloride carbonyl signal. The resulting NCA is precipitated into n-heptane at −5°C, washed with methyl tert-butyl ether, and stored under argon at −20°C with moisture content below 0.1% w/w. For polymerization, the NCA is dissolved in anhydrous N,N-dimethylformamide and initiated with hexamethyldisilazane at a monomer-to-initiator ratio from 100:1 to 500:1, targeting degree of polymerization ranges from 100 to 500; however, published data for unprotected poly(L-tyrosine) prepared from this exact methyl ester hydrochloride route is limited, and the phenolic hydroxyl is frequently protected as the benzyl ether before polymerization to prevent chain transfer or branching. The terminal finished products are poly(L-tyrosine) homopolymers and tyrosine-containing copolypeptides used as research-grade drug delivery nanoparticles and biomedical coating intermediates. Biocompatibility screening for such polymers is performed under ISO 10993-1:2018, elemental impurity release follows ICH Q3D, and if the material is later used in a medical device or combination product, the quality system expectation is ISO 13485:2016 Clause 7.5.

Research-Grade Dipeptide Libraries Emerge from Enzyme-Catalyzed Amidation of Tyrosyl Methyl Ester

Research-grade dipeptide libraries containing N-acyl-L-tyrosine methyl ester fragments are produced by enzyme-catalyzed amidation in a packed-bed reactor charged with immobilized chymotrypsin. The free base is generated from L-tyrosine methyl ester hydrochloride by neutralization with N-methylmorpholine in anhydrous acetonitrile and is then introduced into the aqueous phase at 1.0–1.2 molar equivalents relative to the N-acyl amino acid acyl donor. The enzyme loading is maintained at 0.5–5% w/w of total reactants on a dry carrier basis; the reactor is a 10 mL stainless-steel column with jacketed temperature control at 25–35°C and a substrate flow rate of 0.05–0.20 mL/min. The aqueous phase is 50 mM borate buffer adjusted to pH 8.0, with acetonitrile at 10–20% v/v as a solubility modifier; acetonitrile above 20% v/v causes a measurable drop in enzyme half-life and is not used. Because the free base form undergoes autoxidation at the phenolic hydroxyl, the neutralized methyl ester is blanketed with nitrogen and used within 24 h; long-term storage of the hydrochloride salt at 2–8°C is preferred. The product stream is collected, extracted into ethyl acetate, washed with 0.1 M HCl and brine, and concentrated on a wiped-film evaporator at 35°C and 50 mbar. Published data for continuous packed-bed amidation of this exact tyrosyl methyl ester hydrochloride is limited; the residence time distribution should be verified for each lot of immobilized enzyme, and backflushing with buffer is performed when pressure drop increases across the column. Release testing follows USP 621 for purity and Ph. Eur. 2.2.25 for absorbance when applicable; the laboratory quality system is managed under ISO 9001:2015 Clause 8.5. The terminal finished product types are research-grade N-acyl-L-tyrosine methyl ester dipeptide libraries and enzyme-synthesized reference standards used in pharmaceutical discovery.